Intracellular Income Tax Expense vs Selling And Marketing Expenses Analysis
ITCI Stock | USD 85.45 0.19 0.22% |
Intracellular financial indicator trend analysis is infinitely more than just investigating Intracellular Th recent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Intracellular Th is a good investment. Please check the relationship between Intracellular Income Tax Expense and its Selling And Marketing Expenses accounts. Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Intracellular Th. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in main economic indicators.
Income Tax Expense vs Selling And Marketing Expenses
Income Tax Expense vs Selling And Marketing Expenses Correlation Analysis
The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Intracellular Th Income Tax Expense account and Selling And Marketing Expenses. At this time, the significance of the direction appears to have weak relationship.
The correlation between Intracellular's Income Tax Expense and Selling And Marketing Expenses is 0.32. Overlapping area represents the amount of variation of Income Tax Expense that can explain the historical movement of Selling And Marketing Expenses in the same time period over historical financial statements of Intracellular Th, assuming nothing else is changed. The correlation between historical values of Intracellular's Income Tax Expense and Selling And Marketing Expenses is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Income Tax Expense of Intracellular Th are associated (or correlated) with its Selling And Marketing Expenses. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Selling And Marketing Expenses has no effect on the direction of Income Tax Expense i.e., Intracellular's Income Tax Expense and Selling And Marketing Expenses go up and down completely randomly.
Correlation Coefficient | 0.32 |
Relationship Direction | Positive |
Relationship Strength | Very Weak |
Income Tax Expense
Selling And Marketing Expenses
Most indicators from Intracellular's fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Intracellular Th current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Intracellular Th. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in main economic indicators. As of now, Intracellular's Selling General Administrative is increasing as compared to previous years. The Intracellular's current Tax Provision is estimated to increase to about 667.8 K, while Issuance Of Capital Stock is projected to decrease to 0.00.
2021 | 2022 | 2023 | 2024 (projected) | Net Interest Income | 1.6M | 7.4M | 20.3M | 21.4M | Interest Income | 1.6M | 7.4M | 20.3M | 21.4M |
Intracellular fundamental ratios Correlations
Click cells to compare fundamentals
Intracellular Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Intracellular fundamental ratios Accounts
2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
Total Assets | 251.2M | 717.3M | 489.9M | 754.8M | 728.3M | 410.9M | |
Other Current Liab | 25.6M | 25.8M | 37.9M | 63.7M | 108.5M | 113.9M | |
Total Current Liabilities | 36.2M | 36.9M | 53.4M | 83.2M | 123.5M | 129.7M | |
Total Stockholder Equity | 195.0M | 656.9M | 417.9M | 656.1M | 591.4M | 366.2M | |
Accounts Payable | 7.4M | 5.5M | 8.7M | 10.4M | 11.5M | 6.4M | |
Cash | 107.6M | 60.0M | 92.4M | 148.6M | 147.8M | 74.0M | |
Other Assets | 608.1K | 350.7K | 86.1K | 86K | 98.9K | 94.0K | |
Common Stock Shares Outstanding | 55.2M | 70.4M | 81.3M | 94.0M | 95.9M | 55.1M | |
Short Term Investments | 116.4M | 597.4M | 320.0M | 443.3M | 350.2M | 287.1M | |
Other Current Assets | 6.3M | 15.6M | 26.8M | 46.9M | 42.4M | 44.6M | |
Total Liab | 56.2M | 60.5M | 72.0M | 98.7M | 136.9M | 143.7M | |
Common Stock | 5.6K | 8.0K | 8.2K | 9K | 10K | 6.6K | |
Property Plant Equipment | 2.3M | 2.0M | 22.6M | 1.9M | 2.2M | 3.0M | |
Net Tangible Assets | 195.0M | 656.9M | 417.9M | 656.1M | 754.5M | 792.2M | |
Property Plant And Equipment Net | 20.5M | 26.3M | 22.6M | 16.7M | 14.6M | 9.6M | |
Net Debt | (84.5M) | (30.9M) | (67.0M) | (128.6M) | (130.8M) | (124.3M) | |
Retained Earnings | (710.1M) | (937.1M) | (1.2B) | (1.5B) | (1.6B) | (1.5B) | |
Non Current Assets Total | 20.9M | 26.4M | 22.6M | 16.8M | 60.5M | 63.5M | |
Cash And Short Term Investments | 224.0M | 657.4M | 412.3M | 591.9M | 497.9M | 388.7M | |
Common Stock Total Equity | 5.6K | 8.0K | 8.2K | 9K | 10.4K | 5.5K | |
Retained Earnings Total Equity | (710.1M) | (937.1M) | (1.2B) | (1.5B) | (1.3B) | (1.3B) | |
Liabilities And Stockholders Equity | 251.2M | 717.3M | 489.9M | 754.8M | 728.3M | 443.0M | |
Non Current Liabilities Total | 20.0M | 23.6M | 18.7M | 15.5M | 13.3M | 10.0M | |
Capital Surpluse | 905.0M | 1.6B | 1.6B | 2.1B | 2.5B | 2.6B | |
Other Stockholder Equity | 905.0M | 1.6B | 1.6B | 2.1B | 2.2B | 2.3B | |
Property Plant And Equipment Gross | 20.5M | 26.3M | 1.8M | 1.9M | 14.6M | 15.3M | |
Total Current Assets | 230.3M | 690.9M | 467.3M | 738.0M | 667.8M | 428.9M | |
Accumulated Other Comprehensive Income | 128.3K | 480.6K | (363.7K) | (4.2M) | 104K | 109.2K | |
Net Invested Capital | 195.0M | 656.9M | 417.9M | 656.1M | 591.4M | 516.9M | |
Net Working Capital | 194.1M | 654.1M | 413.9M | 654.7M | 544.3M | 508.4M | |
Capital Stock | 5.6K | 8.0K | 8.2K | 9K | 10K | 8.5K |
Currently Active Assets on Macroaxis
When determining whether Intracellular Th offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Intracellular's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Intracellular Th Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Intracellular Th Stock:Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Intracellular Th. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in main economic indicators. You can also try the Correlation Analysis module to reduce portfolio risk simply by holding instruments which are not perfectly correlated.
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Intracellular. If investors know Intracellular will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Intracellular listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.87) | Revenue Per Share 6.096 | Quarterly Revenue Growth 0.39 | Return On Assets (0.07) | Return On Equity (0.1) |
The market value of Intracellular Th is measured differently than its book value, which is the value of Intracellular that is recorded on the company's balance sheet. Investors also form their own opinion of Intracellular's value that differs from its market value or its book value, called intrinsic value, which is Intracellular's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Intracellular's market value can be influenced by many factors that don't directly affect Intracellular's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Intracellular's value and its price as these two are different measures arrived at by different means. Investors typically determine if Intracellular is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Intracellular's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.